Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 16:2:2.
doi: 10.3389/fonc.2012.00002. eCollection 2012.

The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm

Holly L Spraker  1 , Shawn L Price, Aashi Chaturvedi, Joshua D Schiffman, Kevin B Jones, Stephen L Lessnick, Mary Beckerle, R Lor Randall
Affiliations

The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm

Holly L Spraker et al. Front Oncol. .

Abstract

Ewing sarcoma (ES) is the second most common bone tumor affecting primarily adolescents and young adults. Despite recent advances in biological understanding, intensification of chemotherapeutic treatments, and progress in local control with surgery and/or radiation therapy, patients with metastatic or recurrent ES continue to have a dismal prognosis with less than 20% overall survival. All ES is likely metastatic at diagnosis although our methods of detection and classification may not account for this. Progressive disease may arise via a combination of: (1) selection of chemotherapy-resistant clones in primary tumor, (2) signaling from bone or lung microenvironments that may attract tumor cells to distant locations, and/or (3) genetic changes within the ES cells themselves due to DNA-damaging chemotherapeutic agents or other "hits." These possibilities and the evidence base to support them are explored.

Keywords: Ewing sarcoma; metastatic.

PubMed Disclaimer

References

    1. Armengol G., Tarkkanen M., Virolainen M., Forus A., Valle J., Bohling T., Asko-Seljavaara S., Blomqvist C., Elomaa I., Karaharju E., Kivioja A. H., Siimes M. A., Tukiainen E., Caballín M. R., Myklebost O., Knuutila S. (1997). Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br. J. Cancer 75, 1403–140910.1038/bjc.1997.242 - DOI - PMC - PubMed
    1. Arndt C. A., Crist W. M. (1999). Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341, 342–35210.1056/NEJM199907293410507 - DOI - PubMed
    1. Attiyeh E. F., London W. B., Mosse Y. P., Wang Q., Winter C., Khazi D., McGrady P. W., Seeger R. C., Look A. T., Shimada H., Brodeur G. M., Cohn S. L., Matthay K. K., Maris J. M., Children’s Oncology Group (2005). Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243–225310.1056/NEJMoa052399 - DOI - PubMed
    1. Avigad S., Cohen I. J., Zilberstein J., Liberzon E., Goshen Y., Ash S., Meller I., Kollender Y., Issakov J., Zaizov R., Yaniv I. (2004). The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 100, 1053–105810.1002/cncr.20059 - DOI - PubMed
    1. Bernstein M., Kovar H., Paulussen M., Randall R. L., Schuck A., Teot L. A., Juergens H. (2006). Ewing’s sarcoma family of tumors: current management. Oncologist 11, 503–51910.1634/theoncologist.11-5-503 - DOI - PubMed